For the second approach, monoclonal antibodies were raised against rabbit, rat, mouse and human C6. The two most interesting antibodies were raised against human C6 and inhibited complement-mediated haemolysis in a cell-based assay. Both of these antibodies were species specific, excluding the possibility of testing their therapeutic properties in animal models of complement-mediated disease. Instead, an ex vivo model of cardiopulmonary bypass was established and used to test the ability of these antibodies to block soluble C5b-9 formation. Neither antibody inhibited soluble C5b-9 formation, suggesting that they might be interfering with the insertion of C6 into the cell membrane during MAC assembly.
Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:583727 |
Date | January 2006 |
Creators | Clayton, Lisa Victoria Jane Eynstone |
Publisher | Cardiff University |
Source Sets | Ethos UK |
Detected Language | English |
Type | Electronic Thesis or Dissertation |
Source | http://orca.cf.ac.uk/54080/ |
Page generated in 0.0014 seconds